Table Graph
      published meta-analysis   sensitivity analysis   studies

vitamin C in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsSeet 2021, 2021 (REV) 1.00 [0.02; 50.32] 1.00[0.02; 50.32]Seet 2021, 2021 (REV)10%1,236NAnot evaluable hospitalizationdetailed resultsBengu, 2020 0.59 [0.01; 30.23] 0.59[0.01; 30.23]Bengu, 202010%113NAnot evaluable new illness compatible with Covid-19 detailed resultsBengu, 2020 0.08 [0.01; 0.77] Seet 2021, 2021 (REV) 34.50 [23.90; 49.80] 1.85[0.00; 703.65]Bengu, 2020, Seet 2021, 2021 (REV)296%1,349seriousnot evaluable symptomatic Covid-19detailed resultsSeet (HCQ), 2021 (REV) 1.09 [0.68; 1.76] 1.09[0.68; 1.76]Seet (HCQ), 2021 (REV)10%645NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsSeet (HCQ), 2021 (REV) 2.42 [1.87; 3.12] 2.42[1.87; 3.12]Seet (HCQ), 2021 (REV)10%1,051NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-06-02 11:11 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 523,885 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons